MonoGen, Inc.

MonoGen, Inc.

April 11, 2007 08:31 ET

MonoGen Hires Top Ranked Research Analyst Ryan Rauch to Head its Investor Relations Program

MONTREAL, QUEBEC--(CCNMatthews - April 11, 2007) - This Press Release is Not for Distribution in the United States

MonoGen, Inc. ("Corporation") (TSX:MOG) today is pleased to announce that it has entered into an agreement with Ryan Rauch, a research analyst formerly covering Cytyc Corporation and TriPath Imaging Inc., to develop and execute a broad and in-depth investor relations and communications program to enhance the visibility of MonoGen within the investment community.

Norman J. Pressman, Ph.D., Executive Chairman and Chief Scientific Officer of MonoGen said, "We are enthusiastic about Ryan's new commitment to MonoGen. Mr. Rauch has more than a decade of experience as a Medical Technology and Diagnostics analyst, most recently as a highly ranked analyst at Jefferies & Company and as head of the Jefferies' Medical Technology/Diagnostics Equity Research Team. Previously, Ryan was a highly ranked analyst from various other investment banks including SunTrust Robinson Humphrey, Adams Harkness & Hill, and CIBC World Markets. We are confident that his experience, relationships, and efforts will benefit our existing investors and enable us to gain exposure by effectively reaching and communicating with a broader audience of North American investors."

Ryan Rauch, commenting on his recent engagement with MonoGen, reported, "I believe that MonoGen is one of the best kept secrets in the women's health space and will have a significant impact in the domestic cytology market when the Corporation launches the MonoPrep (liquid-based) Pap Test later this year. I am delighted to be working with MonoGen at such an important time in the Company's history and believe that the story will be extremely well received as we aggressively bring it to the U.S. markets. Further, I believe that MonoGen is exceptionally compelling as it is largely undiscovered, enjoys solid management, a broad intellectual property portfolio, a strong distribution partner in Cardinal Health, and a technology platform (including a very promising pipeline of potential new products in imaging and molecular diagnostics) that should allow it to take significant share from Cytyc and Becton Dickinson (formerly TriPath Imaging Inc.)."

About MonoGen, Inc.

With operational headquarters in the United States (Greater Chicago area), MonoGen is a medical device company developing an integrated suite of fully automated devices (the SAVANT LABORATORY SYSTEM™) for anatomic and molecular pathology laboratories. The SAVANT LABORATORY SYSTEM™ is being designed to automate processes performed by clinical laboratories to reduce their costs, increase throughput, and improve the quality and consistency of results.

The common shares of the Corporation are listed for trading on the Toronto Stock Exchange under the trading symbol "MOG".

Forward-Looking Statements

This press release is not for distribution in the United States.

This press release contains statements that are forward-looking in nature. Statements preceded by the words believe, expect, anticipate, plan, intend, continue, estimate, may, will, and similar expressions are forward-looking statements.

Forward-looking statements are based on the Corporation's beliefs and assumptions based on information available at the time the assumption was made. Forward-looking statements relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, new services, market forces, commitments and technological developments, relating to the Corporation. By its nature, such forward-looking information is subject to various risks and uncertainties which could cause the Corporation's actual results and experience to differ materially from the anticipated results or other expectations expressed. Those risks and uncertainties include, but are not limited to MonoGen's ability to raise additional capital, MonoGen's ability to execute its business plan while maintaining at all times its various regulatory approvals, the performance of its strategic partners including the performance of Cardinal Health in the commercialization of the Corporation's products in the marketplace and the competitive response from existing and potential competitors. Readers are cautioned not to place undue reliance on this forward-looking information, which is given as of the date it is expressed in this document, and the Corporation undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Contact Information

  • MonoGen, Inc.
    Norman J. Pressman, Ph.D.
    Executive Chairman and Chief Scientific Officer
    847-758-4202 (FAX)
    MonoGen, Inc.
    Ryan Rauch
    Investor Relations